Roka Bioscience (ROKA) Misses Q2 EPS by 3c

Roka Bioscience (NASDAQ: ROKA) reported Q2 EPS of ($0.54), $0.03 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.58 million.

For earnings history and earnings-related data on Roka Bioscience (ROKA) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Arena Group to rename as Paradium.AI, ticker changing to PAAI
• CoStar Group acquires Zonda for $800M, adding new home data